Biogen Alzheimer’s Drug Approved

Biogen’s Alzheimer’s Drug Aduhelm Earns FDA Approval

A new treatment option for Alzheimer's is now available

Aduhelm is an advanced therapy that targets amyloid-beta plaque

FDA provides wide leeway for Aduhelm to be prescribed

  • Stage 1: Patient exhibits normal behavior
  • Stage 2: Very mild early changes that include basic forgetfulness
  • Stage 3: Mild but discernible decline
  • Stage 4: Moderate, distinct decline including confusion and memory loss
  • Stage 5: Moderately severe decline that reduces patient self-sufficiency
  • Stage 6: Severely declining patient capabilities
  • Stage 7: Very severe decline that includes physical dysfunction

Biogen clinical and commercial outlook



Get the Medium app

A button that says 'Download on the App Store', and if clicked it will lead you to the iOS App store
A button that says 'Get it on, Google Play', and if clicked it will lead you to the Google Play store
Bare Sky Marketing — Healthcare Content Writing

Authentic, fact-based healthcare content marketing writing for medical, business, academic, patient and consumer audiences